Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, et al.
Nature (2019) Vol. 568, Iss. 7750, pp. 112-116
Open Access | Times Cited: 518

Showing 1-25 of 518 citing articles:

CAR T cells produced in vivo to treat cardiac injury
Joel G. Rurik, István Tombácz, Amir Yadegari, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 91-96
Open Access | Times Cited: 782
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson, Marcela V. Maus
Nature reviews. Cancer (2021) Vol. 21, Iss. 3, pp. 145-161
Open Access | Times Cited: 634
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 497
Targeting macrophages in cancer immunotherapy
Zhaojun Duan, Yunping Luo
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 470
Tuning the Antigen Density Requirement for CAR T-cell Activity
Robbie G. Majzner, Skyler P. Rietberg, Elena Sotillo, et al.
Cancer Discovery (2020) Vol. 10, Iss. 5, pp. 702-723
Open Access | Times Cited: 411
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah, Bryon D. Johnson, Dina Schneider, et al.
Nature Medicine (2020) Vol. 26, Iss. 10, pp. 1569-1575
Closed Access | Times Cited: 373
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 338
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 321
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 290
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
Neha N. Parayath, Sirkka B. Stephan, Amanda Koehne, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 281
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu, Qihang Sun, Xiaoqian Liang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 264
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai, Zhiqiang Wu, Hejin Jia, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 256
Nanomaterials for T-cell cancer immunotherapy
Ningqiang Gong, Neil C. Sheppard, Margaret M. Billingsley, et al.
Nature Nanotechnology (2021) Vol. 16, Iss. 1, pp. 25-36
Closed Access | Times Cited: 244
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell, James N. Kochenderfer
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 11, pp. 715-727
Closed Access | Times Cited: 244
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Chuan Tong, Weidong Han, Yang Liu, et al.
Blood (2020)
Open Access | Times Cited: 229
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 209
Genetically engineered T cells for cancer immunotherapy
Dan Li, Xue Li, Weilin Zhou, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 205
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality
Chaofan Li, Bibo Zhu, Young Min Son, et al.
Immunity (2019) Vol. 51, Iss. 3, pp. 491-507.e7
Open Access | Times Cited: 196
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu, Yali Zhou, Mingming Zhang, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 10, pp. 2764-2772
Open Access | Times Cited: 189
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Meir Rozenbaum, Amilia Meir, Yarden Aharony, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 183
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Blood Advances (2019) Vol. 3, Iss. 22, pp. 3539-3549
Open Access | Times Cited: 173
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
David Marín, Ye Li, Rafet Başar, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 772-784
Open Access | Times Cited: 163
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek, Junji Watanabe, Sujith K. Joseph, et al.
Leukemia (2020) Vol. 35, Iss. 1, pp. 75-89
Open Access | Times Cited: 153
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma
Di Wang, Jue Wang, Guang Hu, et al.
Blood (2021)
Open Access | Times Cited: 150
Tumor microenvironment in glioblastoma: Current and emerging concepts
Pratibha Sharma, Ashley Aaroe, Jiyong Liang, et al.
Neuro-Oncology Advances (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 137
Page 1 - Next Page

Scroll to top